Dental management in Oncology patient: osteonecrosis related osteonecrosis of the Jaw (MRONJ)

P. Noemi
{"title":"Dental management in Oncology patient: osteonecrosis related osteonecrosis of the Jaw (MRONJ)","authors":"P. Noemi","doi":"10.31579/2690-4861/058","DOIUrl":null,"url":null,"abstract":"It is essential that oncological patients treated with antiresorptives or antiangiogenic drugs diagnosed Medication Related Osteonecrosis of the Jaw (MRONJ) must be treated in an interdisciplinary fashion. The patient’s stomatognathic system should be examined preventatively prior to the initiation of antiresorptive drugs in order to avoid pathological buccal manifestations, following the same healthcare clinical protocols used for patients receiving head and neck radiotherapy. Additionally, patients should be informed of the precautions to be taken, including regular dental appointments for oral health assessment. The risk of developing MRONJ should be evaluated according to the type of antiresorptives or antiangiogenic drugs administered and treatment duration. In the case of MRONJ, its fundamental characteristic is positioned in the biochemical particularity of the pharmacokinetic expression of antiresorptive drugs, reversibly (DS) or irreversibly (BPs) inhibiting the functionality of the osteoclast. Therefore, the consideration of invading bone tissue as little as possible and performing resective therapies in cases of systemic infectious spread follows, since its long-term resolution would not be effective because the drug (BPs) has frank accumulation at a distance, a characteristic used by treating doctors and it would not have clinical relevance to suggest its suspension. According to the recommendations of AAOMS; Task Force and AOCMF coincide with the sharing of consensus on minimally invasive manipulations once the necrotic foci have been installed and the preventive attitude prevails of eliminating all septic foci prophylactically before starting therapy with antiresorptive drugs. There are positions with a trend more committed to frank bone manipulation with the aim of evacuating the infectious problem and other more conservative positions in order not to expand drug necrosis volumetrically due to bone accumulation of BPs or DS.","PeriodicalId":347161,"journal":{"name":"International Journal of Computing and Corporate Research","volume":"38 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Computing and Corporate Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31579/2690-4861/058","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

It is essential that oncological patients treated with antiresorptives or antiangiogenic drugs diagnosed Medication Related Osteonecrosis of the Jaw (MRONJ) must be treated in an interdisciplinary fashion. The patient’s stomatognathic system should be examined preventatively prior to the initiation of antiresorptive drugs in order to avoid pathological buccal manifestations, following the same healthcare clinical protocols used for patients receiving head and neck radiotherapy. Additionally, patients should be informed of the precautions to be taken, including regular dental appointments for oral health assessment. The risk of developing MRONJ should be evaluated according to the type of antiresorptives or antiangiogenic drugs administered and treatment duration. In the case of MRONJ, its fundamental characteristic is positioned in the biochemical particularity of the pharmacokinetic expression of antiresorptive drugs, reversibly (DS) or irreversibly (BPs) inhibiting the functionality of the osteoclast. Therefore, the consideration of invading bone tissue as little as possible and performing resective therapies in cases of systemic infectious spread follows, since its long-term resolution would not be effective because the drug (BPs) has frank accumulation at a distance, a characteristic used by treating doctors and it would not have clinical relevance to suggest its suspension. According to the recommendations of AAOMS; Task Force and AOCMF coincide with the sharing of consensus on minimally invasive manipulations once the necrotic foci have been installed and the preventive attitude prevails of eliminating all septic foci prophylactically before starting therapy with antiresorptive drugs. There are positions with a trend more committed to frank bone manipulation with the aim of evacuating the infectious problem and other more conservative positions in order not to expand drug necrosis volumetrically due to bone accumulation of BPs or DS.
肿瘤患者的牙科治疗:骨坏死相关性颌骨骨坏死(MRONJ)
用抗吸收或抗血管生成药物治疗的肿瘤患者诊断为药物相关性颌骨骨坏死(MRONJ)必须以跨学科的方式进行治疗。在开始使用抗吸收药物之前,应预防性检查患者的口颌系统,以避免病理性颊部表现,并遵循与接受头颈部放疗患者相同的医疗保健临床方案。此外,应告知患者应采取的预防措施,包括定期预约牙医进行口腔健康评估。发生MRONJ的风险应根据所使用的抗吸收或抗血管生成药物的类型和治疗时间进行评估。就MRONJ而言,其基本特征定位于抗吸收药物的药代动力学表达的生化特殊性,可逆(DS)或不可逆(bp)抑制破骨细胞的功能。因此,考虑到尽可能少地侵入骨组织,并在全身性感染性传播的情况下进行相应的治疗,因为其长期解决不会有效,因为药物(bp)在远处有明显的积累,这是治疗医生使用的一个特征,并且不具有临床相关性,建议暂停使用。根据AAOMS的建议;Task Force和AOCMF一致认为,一旦坏死灶已经安装,微创操作是一致的,预防态度普遍存在,即在开始抗吸收药物治疗之前预防性地消除所有败血症灶。有一些体位倾向于坦白的骨操作,目的是清除感染问题,还有一些更保守的体位,目的是避免因bp或DS的骨积聚而扩大药物坏死的体积。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信